answer from hershel, page-4

In the review report, it clearly indicated that the company wanted "Pursuing in-licensing, acquisition, co-development, and other similar collaborative clinical-stage development opportunities to better balance its pipeline".

I don't this will be another lie or not.

When PC made the last two crappy acquisitions and the merger deal, he also claimed that thr was for Biota to balance its pipeline. Now it turns out to be a lie. That is , lots of expenses and big shareholder dilutions have been incurred, biota has not added any tiny bit to balance its pipeline. Normal shareholders would get outrage over this. I know some PC management stooges would disagree with me. But that is just what I,a disappointed shareholder, think.